Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/32422057 below:

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure

Review

Affiliations

• ¹ Johns Hopkins School of Medicine, Baltimore, Maryland (L.M.K.).
• ² Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (S.A.L., D.B., J.L.).
• ³ Johns Hopkins School of Medicine, Johns Hopkins Bloomberg School of Public Health, and National Institute of Allergy and Infectious Diseases, Baltimore, Maryland (O.L.).

• PMID: 32422057
• PMCID: PMC7240870
• DOI: 10.7326/M20-1495

Item in Clipboard

Review

Lauren M Kucirka et al. Ann Intern Med. 2020.

• ¹ Johns Hopkins School of Medicine, Baltimore, Maryland (L.M.K.).
• ² Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (S.A.L., D.B., J.L.).
• ³ Johns Hopkins School of Medicine, Johns Hopkins Bloomberg School of Public Health, and National Institute of Allergy and Infectious Diseases, Baltimore, Maryland (O.L.).

• PMID: 32422057
• PMCID: PMC7240870
• DOI: 10.7326/M20-1495

Item in Clipboard

Background: Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse transcriptase polymerase chain reaction (RT-PCR) are being used to rule out infection among high-risk persons, such as exposed inpatients and health care workers. It is critical to understand how the predictive value of the test varies with time from exposure and symptom onset to avoid being falsely reassured by negative test results.

Objective: To estimate the false-negative rate by day since infection.

Design: Literature review and pooled analysis.

Setting: 7 previously published studies providing data on RT-PCR performance by time since symptom onset or SARS-CoV-2 exposure using samples from the upper respiratory tract (n = 1330).

Patients: A mix of inpatients and outpatients with SARS-CoV-2 infection.

Measurements: A Bayesian hierarchical model was fitted to estimate the false-negative rate by day since exposure and symptom onset.

Results: Over the 4 days of infection before the typical time of symptom onset (day 5), the probability of a false-negative result in an infected person decreases from 100% (95% CI, 100% to 100%) on day 1 to 67% (CI, 27% to 94%) on day 4. On the day of symptom onset, the median false-negative rate was 38% (CI, 18% to 65%). This decreased to 20% (CI, 12% to 30%) on day 8 (3 days after symptom onset) then began to increase again, from 21% (CI, 13% to 31%) on day 9 to 66% (CI, 54% to 77%) on day 21.

Limitation: Imprecise estimates due to heterogeneity in the design of studies on which results were based.

Conclusion: Care must be taken in interpreting RT-PCR tests for SARS-CoV-2 infection-particularly early in the course of infection-when using these results as a basis for removing precautions intended to prevent onward transmission. If clinical suspicion is high, infection should not be ruled out on the basis of RT-PCR alone, and the clinical and epidemiologic situation should be carefully considered.

Primary funding source: National Institute of Allergy and Infectious Diseases, Johns Hopkins Health System, and U.S. Centers for Disease Control and Prevention.

PubMed Disclaimer

Sensitivity of RT-PCR tests, by…

Sensitivity of RT-PCR tests, by study and days since symptom onset, for nasopharyngeal…

Sensitivity of RT-PCR tests, by study and days since symptom onset, for nasopharyngeal samples (left), oropharyngeal samples (middle), and unspecified upper respiratory tract (right). RT-PCR = reverse transcriptase polymerase chain reaction.

Probability of having a negative…

Probability of having a negative RT-PCR test result given SARS-CoV-2 infection ( top…

Probability of having a negative RT-PCR test result given SARS-CoV-2 infection (top) and of being infected with SARS-CoV-2 after a negative RT-PCR test result (bottom), by days since exposure. RT-PCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Posttest probability of SARS-CoV-2 infection…

Posttest probability of SARS-CoV-2 infection after a negative RT-PCR result, by pretest probability…

Posttest probability of SARS-CoV-2 infection after a negative RT-PCR result, by pretest probability of infection. RT-PCR = reverse transcriptase polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

• Antibody tests for identification of current and past infection with SARS-CoV-2. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft L, Leeflang MM, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Deeks JJ, et al. Cochrane Database Syst Rev. 2020 Jun 25;6(6):CD013652. doi: 10.1002/14651858.CD013652. Cochrane Database Syst Rev. 2020. PMID: 32584464 Free PMC article. Updated.
• At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data.

  Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS, Green K, Suklan J, Hyde C, Shinkins B, Zhelev Z, Peters J, Turner PJ, Roberts NW, di Ruffano LF, Wolff R, Whiting P, Winter A, Bhatnagar G, Nicholson BD, Halligan S. Mallett S, et al. BMC Med. 2020 Nov 4;18(1):346. doi: 10.1186/s12916-020-01810-8. BMC Med. 2020. PMID: 33143712 Free PMC article.

• [SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].

  Erensoy S. Erensoy S. Mikrobiyol Bul. 2020 Jul;54(3):497-509. doi: 10.5578/mb.69839. Mikrobiyol Bul. 2020. PMID: 32755524 Review. Turkish.

• Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.

  Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J. Emadi A, et al. Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.

• Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.

  Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, Taylor M, Cunningham J, Davenport C, Dittrich S, Emperador D, Hooft L, Leeflang MM, McInnes MD, Spijker R, Verbakel JY, Takwoingi Y, Taylor-Phillips S, Van den Bruel A, Deeks JJ; Cochrane COVID-19 Diagnostic Test Accuracy Group. Dinnes J, et al. Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article. Review.

• Right heart catheterization for pulmonary hypertension during the coronavirus disease 2019 pandemic.

  Qaiser KN, Lane JE, Tonelli AR. Qaiser KN, et al. Pulm Circ. 2020 Sep 16;10(3):2045894020948783. doi: 10.1177/2045894020948783. eCollection 2020 Jul-Sep. Pulm Circ. 2020. PMID: 32983409 Free PMC article. Review.

• Screening Testing for SARS-CoV-2 upon Admission to Rehabilitation Hospitals in a High COVID-19 Prevalence Community.

  Kirshblum SC, DeLauter G, Lopreiato MC, Pomeranz B, Dawson A, Hammerman S, Gans BM. Kirshblum SC, et al. PM R. 2020 Oct;12(10):1009-1014. doi: 10.1002/pmrj.12454. Epub 2020 Aug 31. PM R. 2020. PMID: 32700434 Free PMC article.

• Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings.

  Andrey DO, Yerly S, Meyer B, Arm-Vernez I, Roux-Lombard P, Togni G, Guessous I, Spechbach H, Stringhini S, Agoritsas T, Stirnemann J, Reny JL, Siegrist CA, Eckerle I, Kaiser L, Vuilleumier N. Andrey DO, et al. J Clin Med. 2021 Apr 10;10(8):1605. doi: 10.3390/jcm10081605. J Clin Med. 2021. PMID: 33920076 Free PMC article.

• Urological Surgeries During Exit from National Lockdown During COVID-19 Pandemic.

  Bansal D, Chaturvedi S, Kumar A. Bansal D, et al. Indian J Surg. 2021 Feb;83(1):385-387. doi: 10.1007/s12262-020-02571-7. Epub 2020 Sep 7. Indian J Surg. 2021. PMID: 32921944 Free PMC article. No abstract available.

• Back to normal; serological testing for COVID-19 diagnosis unveils missed infections.

  Tsuchida T, Nitahara Y, Suzuki S, Komase Y, Candray K, Kido Y, Nakagama Y, Yamasaki Y, Imamura M, Kawahata K, Kunishima H, Fujitani S, Mineshita M, Matsuda T. Tsuchida T, et al. J Med Virol. 2021 Jul;93(7):4549-4552. doi: 10.1002/jmv.26949. Epub 2021 Mar 25. J Med Virol. 2021. PMID: 33739483 Free PMC article.

1. 1. The Lancet. COVID-19: protecting health-care workers [Editorial]. Lancet. 2020;395:922. [PMID: 32199474] doi:10.1016/S0140-6736(20)30644-9. - PMC - PubMed
2. 1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). 2020. Accessed at www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html. on 31 March 2020.
3. 1. Johns Hopkins Bloomberg School of Public Health. 2019 Novel Coronavirus Research Compendium (NCRC). 2020. Accessed at https://ncrc.jhsph.edu. on 8 May 2020.
4. 1. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020. [PMID: 32235945] doi:10.1038/s41586-020-2196-x. - PubMed
5. 1. Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020. [PMID: 32198501] doi:10.1093/cid/ciaa310. - PMC - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3